Pathology-Driven Comprehensive Proteomic Profiling of the Prostate Cancer Tumor Microenvironment
- PMID: 28057717
- DOI: 10.1158/1541-7786.MCR-16-0358
Pathology-Driven Comprehensive Proteomic Profiling of the Prostate Cancer Tumor Microenvironment
Abstract
Prostate cancer is the second most common cancer in men worldwide. Gleason grading is an important predictor of prostate cancer outcomes and is influential in determining patient treatment options. Clinical decisions based on a Gleason score of 7 are difficult as the prognosis for individuals diagnosed with Gleason 4+3 cancer is much worse than for those diagnosed with Gleason 3+4 cancer. Laser capture microdissection (LCM) is a highly precise method to isolate specific cell populations or discrete microregions from tissues. This report undertook a detailed molecular characterization of the tumor microenvironment in prostate cancer to define the proteome in the epithelial and stromal regions from tumor foci of Gleason grades 3 and 4. Tissue regions of interest were isolated from several Gleason 3+3 and Gleason 4+4 tumors using telepathology to leverage specialized pathology expertise to support LCM. Over 2,000 proteins were identified following liquid chromatography tandem mass spectrometry (LC-MS/MS) analysis of all regions of interest. Statistical analysis revealed significant differences in protein expression (>100 proteins) between Gleason 3 and Gleason 4 regions-in both stromal and epithelial compartments. A subset of these proteins has had prior strong association with prostate cancer, thereby providing evidence for the authenticity of the approach. Finally, validation of these proteins by immunohistochemistry has been obtained using an independent cohort of prostate cancer tumor specimens.Implications: This unbiased strategy provides a strong foundation for the development of biomarker protein panels with significant diagnostic and prognostic potential. Mol Cancer Res; 15(3); 281-93. ©2017 AACR.
©2017 American Association for Cancer Research.
Similar articles
-
The Proteome of Primary Prostate Cancer.Eur Urol. 2016 May;69(5):942-52. doi: 10.1016/j.eururo.2015.10.053. Epub 2015 Dec 2. Eur Urol. 2016. PMID: 26651926
-
High serum dihydrotestosterone examined by ultrasensitive LC-MS/MS as a predictor of benign prostatic hyperplasia or Gleason score 6 cancer in men with prostate-specific antigen levels of 3-10 ng/mL.Andrology. 2017 Mar;5(2):262-267. doi: 10.1111/andr.12294. Epub 2016 Nov 3. Andrology. 2017. PMID: 27813361
-
Use of two gene panels for prostate cancer diagnosis and patient risk stratification.Tumour Biol. 2016 Aug;37(8):10115-22. doi: 10.1007/s13277-015-4619-0. Epub 2016 Jan 28. Tumour Biol. 2016. PMID: 26820133
-
Contemporary Gleason Grading of Prostatic Carcinoma: An Update With Discussion on Practical Issues to Implement the 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma.Am J Surg Pathol. 2017 Apr;41(4):e1-e7. doi: 10.1097/PAS.0000000000000820. Am J Surg Pathol. 2017. PMID: 28177964
-
The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: Definition of Grading Patterns and Proposal for a New Grading System.Am J Surg Pathol. 2016 Feb;40(2):244-52. doi: 10.1097/PAS.0000000000000530. Am J Surg Pathol. 2016. PMID: 26492179 Review.
Cited by
-
Quantitative Mass Spectrometry-Based Proteomic Profiling for Precision Medicine in Prostate Cancer.Front Oncol. 2017 Nov 7;7:267. doi: 10.3389/fonc.2017.00267. eCollection 2017. Front Oncol. 2017. PMID: 29164064 Free PMC article. Review.
-
The Mitochondrial Proteome of Tumor Cells: A SnapShot on Methodological Approaches and New Biomarkers.Biology (Basel). 2020 Dec 18;9(12):479. doi: 10.3390/biology9120479. Biology (Basel). 2020. PMID: 33353059 Free PMC article. Review.
-
Direct molecular dissection of tumor parenchyma from tumor stroma in tumor xenograft using mass spectrometry-based glycoproteomics.Oncotarget. 2018 May 29;9(41):26431-26452. doi: 10.18632/oncotarget.25449. eCollection 2018 May 29. Oncotarget. 2018. PMID: 29899869 Free PMC article.
-
Integrative proteomics in prostate cancer uncovers robustness against genomic and transcriptomic aberrations during disease progression.Nat Commun. 2018 Mar 21;9(1):1176. doi: 10.1038/s41467-018-03573-6. Nat Commun. 2018. PMID: 29563510 Free PMC article.
-
Ion Channel Profiling in Prostate Cancer: Toward Cell Population-Specific Screening.Rev Physiol Biochem Pharmacol. 2021;181:39-56. doi: 10.1007/112_2020_22. Rev Physiol Biochem Pharmacol. 2021. PMID: 32737754 Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical